GlassScriptPhysician profile
Brittany Johnson
NPI 1336853480
$2,336.18
in general payments reported to CMS, 2019-2025
24 companies · $44.27 in 2025
The $44.27 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,138 · 2024: $154 · 2025: $44.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $553.76 | 2023-2024 | |
| Novo Nordisk INC | $405.90 | 2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $260.85 | 2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Exact Sciences Corporation | $158.22 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.81 | 2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $116.64 | 2023 | Repatha |
| Lilly USA, LLC | $101.29 | 2023 | Jardiance |
| Corcept Therapeutics | $78.14 | 2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $74.12 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.53 | 2023 | |
| Corium, LLC | $70.62 | 2023 | Azstarys |
| Becton, Dickinson and Company | $44.27 | 2025 | Hemosphere |
| Halozyme INC | $39.41 | 2023 | |
| Janssen Pharmaceuticals, INC | $31.93 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $27.51 | 2023 | Farxiga |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $22.96 | 2023 | Belbuca |
| Alkermes, INC. | $20.23 | 2023 | Aristada, Lybalvi |
| Dynavax Technologies Corporation | $18.72 | 2023 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $18.59 | 2023 | Trintellix |
| Axsome Therapeutics, INC. | $18.43 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $17.72 | 2023 | Vaxneuvance, Rotateq, Vaxelis |
| Pfizer INC. | $16.90 | 2023 | |
| Indivior INC. | $15.60 | 2023 | Sublocade |
| Neurocrine Biosciences, INC. | $14.03 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.